Clot composition and recanalization outcomes in mechanical thrombectomy - PubMed (original) (raw)

© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.

Conflict of interest statement

Competing interests: RGN reported consulting fees for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Hybernia, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby, and Synchron and stock options for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, RapidPulse, and Perfuze, and investments in Viz-AI, Perfuze, Cerebrotech, Reist/Q’Apel Medical, Truvic, and Viseon. WB is a consulting medical director for MIVI Neurovascular, consultant for Cerenovus, Microvention, Stryker, Medtronic, Imperative Care and receives research funding from Cerenovus, Brainomix, NIH. ARA-B is a consultant for Stryker Neurovascular. RAH is a consultant for Stryker, Medtronic, Cerenovous, Microvention, Balt, Phenox, Rapid Medical, and Q’Apel. He is on the advisory board for MiVI, eLum, Three Rivers, Shape Medical, and Corindus. AJY receives grants from Medtronic, Cerenovus, Penumbra, Stryker, and Penumbra. He is a consultant for Cerenovus, Penumbra, Vesalio, Zoll, Philips, Rapid Medical, and StrokeNet (MOST trial). AJY also has equity interest in Insera Therapeutics and Nicolab. MJG has been a consultant on a fee-per-hour basis for Alembic LLC, Astrocyte Pharmaceuticals, BendIt Technologies, Cerenovus, Imperative Care, the Jacob’s Institute, Medtronic Neurovascular, Mentice, Mivi Neurosciences, phenox GmbH, Q’Apel, Route 92 Medical, Scientia, Stryker, Wallaby Medical; holds stock in Imperative Care, InNeuroCo, Galaxy Therapeutics and Neurogami; and has received research support from the National Institutes of Health (NIH), the United States – Israel Binational Science Foundation, Anaconda, ApicBio, Arsenal Medical, Axovant, Balt, Cerenovus, Ceretrieve, CereVasc LLC, Cook Medical, Galaxy Therapeutics, Gentuity, Gilbert Foundation, Imperative Care, InNeuroCo, Insera, Jacob’s Institute, Magneto, Microvention, Medtronic Neurovascular, MIVI Neurosciences, Naglreiter MDDO, Neurogami, Philips Healthcare, Progressive Medical, Pulse Medical, Rapid Medical, Route 92 Medical, Scientia, Stryker Neurovascular, Syntheon, ThrombX Medical, Wallaby Medical, the Wyss Institute and Xtract Medical. KD is supported by a grant from Science Foundation Ireland (SFI) and the European Regional Development Fund (ERDF) under grant number 13/RC/2073_P2. ASP is a consultant for Medtronic Neurovascular, Stryker Neurovascular, Balt, Q’Apel Medical, Cerenovus, Microvention, Imperative Care, Agile, Merit, CereVasc and Arsenal Medical and receives research grants from NIH, Microvention. DCH is a consultant for Stryker,Cerenovus and is a member of the Data and Safety Monitoring Board for Vesalio and Jacobs Institute. He also holds stock options of VizAI. The other authors have no competing interests to disclose.